Lifeway Foods: 27 straight quarters of growth — and the company still earns no more than it did three years ago

There is an investor trap that springs precisely when everything looks good — the streak trap. It works like this: a company reports its twenty-ninth, thirtieth, twenty-seventh best quarter in a row. The mind hears "twenty-seven consecutive quarters" and puts the homework aside, because a streak feels like proof. It is not. A streak proves only that one single number went up. At Lifeway Foods (Nasdaq: LWAY) of Morton Grove near Chicago, that single number is net sales, and it really has risen without interruption for almost seven years. What happened alongside it is not in the headline of the press release but twelve pages deeper into the quarterly report filed with the U.S. Securities and Exchange Commission. So let us make a deal: before you buy the streak, we read together what the company itself reported — the Form 10-Q for the quarter ended June 30, 2026, the annual reports (10-K) for 2023 through 2025, the current reports (8-K) of the past two years, the prospectus supplement covering the anchor shareholder's exit and the 2026 proxy statement. An SEC filing is made under penalty of law: false statements in one are a criminal offence. And this one tells the story of a family business that has sold kefir for forty years, that sells more of it every year — and that still earns no more today than it did three years ago. In the end, you decide.

What Lifeway Foods actually sells — 85 percent kefir in a bottle

Kefir is a cultured milk drink: tangy, thicker than buttermilk, full of live cultures — an everyday staple in Eastern Europe, for a long time a niche in the United States. Lifeway Foods essentially created that niche in America. Michael Smolyansky founded the company in 1986, ten years after he and his family emigrated from Eastern Europe to the United States; since her father's death in June 2002 his daughter Julie Smolyansky has run the business as chief executive. By its own account Lifeway was the first company to introduce kefir to U.S. consumers on a commercial scale and is today the country's largest kefir producer. The drink is sold under the Lifeway, Fresh Made and GlenOaks Farms brands and as private label for individual chains.

What stands out is the concentration. The 2025 annual report breaks net sales down by category: drinkable kefir excluding the children's ProBugs line brought in 181.4 million dollars — 85 percent of total net sales of 212.5 million. A year earlier it was 82 percent. Everything else is small: European-style soft cheeses 16.6 million (8 percent), cream and by-products 8.7 million (4 percent), drinkable yogurt 2.3 million (1 percent), ProBugs 2.2 million (1 percent), other dairy 1.3 million (1 percent). The new products management talks about so much — the Muscle Mates protein-and-creatine drink, the kefir butter, the licence for partner Open Farm's dog food — do not appear in that table at all yet. Hold on to this image: Lifeway is not a broad-line dairy, it is one bottle with a company built around it.

Almost everything is made in house: 95 percent of 2025 net sales came from the company\'s own plants (Morton Grove in Illinois, Waukesha in Wisconsin, Philadelphia in Pennsylvania; plus a pure warehouse and distribution site in Niles, Illinois), only 5 percent from co-packers — one of them in Ireland, serving the European market. Fifty-one percent of net sales go directly to retail chains, 47 percent through distributors and 2 percent via the company's own trucks in metropolitan Chicago. Seven percent of net sales go abroad, mostly to Mexico, Central America and the Caribbean. And here is the first number worth remembering: two retail customers alone accounted for 24 percent of 2025 net sales and 24 percent of net receivables; in the first half of 2026 it was 25 percent. The filing does not say who they are — only how much depends on them. That sets the central tension of this analysis, and it runs through every chapter: a single product, sold through a handful of chains, has grown without interruption for seven years — and it is exactly that narrowness which decides whether any of the growth turns into profit.

The numbers over the years — an honest look

First what genuinely speaks for Lifeway, and there is plenty. Net sales have hit a new high four years running, and they rise on volume rather than price — management calls its growth "volume-led" on every call. The sequence of fiscal years:

The balance sheet also looks orderly. At June 30, 2026, total assets of 132.4 million dollars faced liabilities of 47.8 million; equity stood at 84.6 million, or 64 percent of total assets. There is no going-concern language, no impairment of the 11.7 million dollar goodwill balance, and the financial covenants agreed with the lender were met at the reporting date. For a company of this size, that is a sound footing.

Now the number that appears in no headline. Operating income — what is left after all the costs of running the business, before interest and taxes — went like this: 17.0 million dollars in 2023, 13.9 million in 2024, 16.2 million in 2025. Over the same period net sales rose from 160.1 to 212.5 million, a third more. Operating income did not. Put plainly: Lifeway has added 52 million dollars of annual net sales in three years and earns less on the bottom operating line than before. The operating margin fell from 10.6 percent (2023) to 7.5 percent (2025).

Part of that is explainable and even defensible: selling expenses rose from 14.7 million (2024) to 19.9 million dollars (2025) because the company is investing heavily in advertising and sampling — a deliberate choice, and the sales line vindicates it. Another part is not. The annual report puts the legal and professional fees connected with Danone's takeover proposal and "non-routine stockholder action" at approximately 6.2 million dollars in 2025 and approximately 4.5 million in 2024 — 10.7 million dollars in total that went to lawyers and advisers; for 2024 the report names a third occasion alongside them, the retention bonus agreement for the chief executive. That equals two thirds of the entire 2025 operating income. And the 2025 net income of 13.9 million carries a one-off item: a 3.4 million dollar gain on the sale of the company's Simple Mills investment. Without it, the figure celebrated as "54 percent net income growth" would have been considerably smaller.

What the filings reveal — the uncomfortable truths

First: margin collapsed in the second quarter of 2026 — and hard. On August 13, 2026 Lifeway reported the highest quarterly net sales in company history: 66.9 million dollars, 24.1 percent above the prior-year quarter. The same filing shows what was left of it: 0.1 million dollars of net income, 0.01 dollars per share — against 4.3 million and 0.28 dollars per share a year earlier. The cause is gross margin, the share of net sales left after the pure cost of making the product:

The company names the cause itself in the quarterly report:

“Gross profit as a percentage of net sales was 19.5% and 28.6% in the three-month period ended June 30, 2026 and 2025, respectively. The decrease versus the prior year was driven by the unfavorable impact of milk pricing and to a lesser extent the unfavorable impact of resin-based packaging inputs and transportation costs.”

— Lifeway Foods, Inc., Form 10-Q for the quarter ended June 30, 2026, "Gross Profit"

Milk prices are weather, not management — that is a fair objection. But it cuts both ways: on the calls for the third and fourth quarters of 2025 and the first quarter of 2026, management attributed the margin improvement in part to "favorable conventional milk pricing". When the same factor is booked as skill on the way up and as weather on the way down, the story does not agree with itself. The annual report explicitly calls milk "our primary raw material" — a commodity whose minimum prices U.S. federal authorities set every month — and the risk section says what can follow: that customer pricing actions may lag input cost changes, or that the full effect of higher input costs may not be passed on. The defensible conclusion is therefore: a business whose primary raw material carries a government-set minimum price earns reliably only if it can push price increases through the trade — and that is exactly the open question.

Second: growth now consumes more cash than it brings in. In the first half of 2026 the business generated 4.0 million dollars of operating cash flow. Over the same period 19.5 million went into property and equipment — almost all of it into the Waukesha expansion. That leaves a gap of some 15 million, and the bank filled it. The filing is unambiguous here:

Cash stood at 7.1 million dollars at the reporting date; a year earlier it was 21.2 million. The rate on the drawn facility was 5.48 percent, and the lender requires a fixed charge coverage ratio of at least 1.25 and a cash flow leverage ratio of no more than 2.00 — both were met at June 30, 2026. For the remainder of the plant build-out the company signed an additional equipment financing facility of up to 22.0 million dollars with the same bank on June 30, 2026 (SOFR plus 1.65 percent, interim funding period to June 30, 2027). It was undrawn at the reporting date. So the funding is arranged — it is simply debt, and it costs interest in a year in which second-quarter operating income shrank to 0.6 million dollars.

Third: the plant got more expensive and later — without a separate announcement. On the third-quarter 2025 call the chief executive named "approximately $45,000,000 in capital expenditures" for the Waukesha expansion and completion of the project "in 2026". The quarterly report for the period ended June 30, 2026 says: "The Company currently estimates investing approximately $50,500" — 50.5 million dollars. Completion is now scheduled "during the first fiscal quarter of 2027", with production at the larger scale beginning in January 2027. Cash paid through June 30, 2026 was 38.9 million, of which 27.9 million sits in construction in process. The 5.5 million dollar overrun appears in the quarterly report only; the new date shows up in the earnings release of August 13, 2026 merely in passing ("the planned completion of our transformative Waukesha expansion in early 2027"), with no indication that it differs from the earlier guidance. There was no separate announcement of the change.

Fourth: a quarter of net sales depends on two customers. The 2025 annual report names two retail customers accounting together for 24 percent of net sales and 24 percent of receivables; in the first half of 2026 it was 25 percent. In U.S. food retail that is not unusual — the trade is concentrated, and Lifeway itself flags the concentration as a risk. It is not existential. But it limits exactly the ability the company needs right now: passing higher milk costs on to customers. Whoever has a quarter of their revenue with two counterparties does not negotiate from strength.

Who owns the company — and why the buyer walked away

The most interesting story at Lifeway is not in the income statement but in the chapter on shareholders. Four parties hold roughly three quarters of the company, and three of them share a surname.

The 2025 annual report states the position as of December 31, 2025 plainly: Julie Smolyansky, the chief executive and daughter of the founder, held about 18 percent; Edward Smolyansky, her brother and the company's former chief operations officer, about 20 percent; Ludmila Smolyansky, the mother and the founder's widow, about 6 percent; Danone North America about 23 percent; and the investment firm Divisadero about 9 percent. The 2026 proxy statement gives the precise figures as of April 30, 2026: Julie Smolyansky 2,678,767 shares (17.52 percent), Edward Smolyansky 2,927,632 (19.61 percent), Ludmila Smolyansky 807,823 (5.29 percent), Danone 3,454,756 (22.61 percent), Divisadero 1,347,635 (8.82 percent). Do the arithmetic and the point is immediate: brother and mother together hold 24.90 percent — more than the chief executive.

The filing draws the conclusion itself:

“It is unlikely that any person interested in acquiring Lifeway will be able to do so without obtaining the consent of some combination of Julie Smolyansky, Edward Smolyansky, Ludmila Smolyansky, Danone and Divisadero.”

— Lifeway Foods, Inc., Form 10-K for 2025, Item 1A Risk Factors

That is precisely where the takeover failed. On September 23, 2024 Danone — tied to the founding family since a stockholders' agreement dated October 1, 1999 — offered 25.00 dollars per share for the shares it did not already own. The board rejected it on November 5, 2024 as substantially undervaluing the company. On the same day it adopted a classic takeover defence, a shareholder rights plan that massively dilutes anyone acquiring 20 percent or more. On November 15, 2024 Danone raised its offer to 27.00 dollars per share. On November 20, 2024 the board rejected it again.

What followed was eighteen months of trench warfare: Danone sued in the Circuit Court of Cook County to enforce the 1999 stockholders\' agreement, and Edward Smolyansky ran his own campaign against the board in 2025. How seriously the company took it shows in the cooperation agreement itself: it expressly covers the case that Edward or Ludmila Smolyansky calls a special meeting or commences a consent solicitation — in which case Danone votes with the board. On September 30, 2025 the company and Danone settled in a cooperation agreement: the board was refreshed with four new independent directors unaffiliated with the family and with Danone; Danone waived its right to board representation; the litigation was jointly stayed — and the company registered Danone's shares for resale.

The rest is quickly told and, for shareholders, the actual news. On May 14, 2026 Danone placed its entire block of 3,454,756 shares at 19.50 dollars through the bank BTIG. The bank paid Danone 18.425 dollars per share, roughly 63.6 million in total. The prospectus supplement carries the comparison on the same page: the last reported sale price on May 13, 2026 was 27.25 dollars.

Lifeway itself repurchased 4.9 million dollars of stock out of that placement — paid in a half-year in which 23 million dollars of bank debt were drawn. On June 5, 2026 the board redeemed the rights plan, paying holders 0.001 dollars per right. At the annual meeting on June 17, 2026 every board nominee was elected — but not unanimously: 3,536,740 shares voted against Julie Smolyansky out of 13,982,124 shares represented, and 3,347,326 against the compensation resolution. Roughly a quarter of the votes cast still stands against the board. And the cooperation agreement has a side effect the proxy statement states openly: the company may not grant equity compensation to the chief executive and her family. That is why previously vested share awards held by the chief executive were settled in cash for 283,000 dollars in the first quarter of 2026.

What management said on the calls — and what it actually delivered

Three transcripts of Lifeway's earnings presentations are available to us: the third quarter of 2025 (November 12, 2025), the fourth quarter and full year 2025 (March 17, 2026) and the first quarter of 2026 (May 14, 2026). No transcript of the most recent report, for the second quarter of 2026, was available at the time of writing; there our reading rests on the earnings release of August 13, 2026.

The first finding concerns not the content but the format — and it is unusual enough to come first: none of the three transcripts contains a question-and-answer section. Each ends with a word of thanks and a sign-off once the chief executive has read out her prepared remarks. According to the introduction, only one executive is present on each call — the chief financial officer appears on none of the three recordings. And the August 13, 2026 earnings release does not invite analysts to a call; it points to a "webcast", that is, a recording on the company website. For our analyses the question-and-answer section is normally the most valuable part: that is where the follow-ups happen, where a management team dodges, where the sentences arise against which it can later be measured. At Lifeway that part does not exist. Anyone wanting to know how management answers an uncomfortable question will not find out — because the question cannot be asked.

What can still be checked is how the statements match what later appeared in the filings. Three points:

The plant expansion. In November 2025 the company said it had "to date, in 2025, […] invested over 9,000,000 in this project" and estimated the total at "approximately $45,000,000"; full capacity would come "upon completion of the project in 2026". In March 2026 it was still the "$45 million Waukesha expansion". In May 2026 the project remained "on track for completion by the end of this year" — while the same passage said the full effect would arrive "once the full initiative comes online in Q1 2027". The quarterly report of August 13, 2026 then gives 50.5 million dollars and the first quarter of 2027. The distance between the first statement and the latest filing is 5.5 million dollars and roughly one quarter.

Milk prices. In November 2025 the margin improvement was attributed in part to "favorable conventional milk pricing", in March 2026 to "the favorable impact of conventional milk pricing", in May 2026 to "favorable conventional milk pricing during that period". In August 2026 the same factor is "the primary margin headwind" and the pressure is described as "temporary". Both can be true — but it shows that this company's margin depends far more, in both directions, on the milk price than on its own execution.

The 2027 profit target. On the calls in November 2025 and March 2026 the chief executive expressly reaffirmed a profit target for 2027; in March 2026 in her own words: "$45 million to $50 million in adjusted EBITDA for fiscal year 2027" — adjusted earnings before interest, taxes, depreciation and amortisation of 45 to 50 million dollars in 2027. For context: 2025 operating income was 16.2 million and depreciation and amortisation about 4.0 million. In the second-quarter 2026 earnings release of August 13, 2026 the word "EBITDA" no longer appears; instead the company says gross margin and profitability will "fully recover in 2027". Anyone holding that 2027 target in mind holds the single most important number against which this management can be measured — and should check the next filing to see whether it is still stated.

Valuation: what the market is paying for Lifeway Foods

At a price of 26.35 dollars (as of August 28, 2026) and 15,106,747 shares outstanding (as of August 7, 2026), Lifeway is valued at roughly 398 million dollars. Measured against net sales of the last four reported quarters (242.4 million) that is a price-to-sales ratio of about 1.6. Measured against net income of the same four quarters (10.9 million) it is a price-to-earnings ratio of about 37 — and that is where the argument starts: 37 is a multiple you expect from a fast-growing branded consumer company, not from a dairy processor running a 7.5 percent operating margin. Book value per share was 5.60 dollars at June 30, 2026, so the price is a good four and a half times equity. Add net debt of roughly 15 million dollars and enterprise value comes to about 413 million, or a good twenty times trailing four-quarter earnings before interest, taxes, depreciation and amortisation.

Two things qualify every one of those numbers. First, the earnings denominator has just collapsed — a price-to-earnings ratio built on a quarter with 0.1 million dollars of profit says little about what the business earns in a normal year. Anyone who believes margin returns to the old 27 percent in 2027 is working with an entirely different denominator. Anyone who does not is working with a worse one. Second, trading is thin: of the 15.1 million shares only about 6.5 million are in free float, the rest sits with the family and institutional holders. The 52-week range ran from 17.31 to 34.20 dollars (as of August 28, 2026) — close to a factor of two within a year, in a stock whose measured sensitivity to the broad market is only about 0.46. Translated: the price moves do not come from the market, they come from the company.

And then there is the price anchor no valuation model supplies, but the company's own history does: a strategic buyer who knew the business from the inside thought the company worth 27.00 dollars per share in November 2024 — and sold eighteen months later at 19.50. Anyone buying today pays more than the price at which the best-informed seller got out. That is not a verdict, but it is a number worth knowing. We have described comparable patterns in the food sector in our analysis of Freshpet and, on the retail side, in our analysis of Sprouts Farmers Market.

Opportunities and risks at a glance

What speaks for the company. Demand is real and not manufactured: 27 consecutive quarters of growth, carried by volume rather than price. The category has a tailwind — protein, gut health and fermented foods have been consumer trends for years, and by its own account in the annual report Lifeway is the largest kefir producer in the United States. The balance sheet carries the business, equity is just under two thirds of total assets, and the debt funding of the plant build-out is arranged through two facilities. Doubling capacity at Waukesha from the start of 2027 is precisely the investment a manufacturer running into a capacity ceiling has to make, and it should lower the cost per bottle.

What speaks against it. Earning power is not keeping pace with revenue: operating income in 2025 was below 2023, on a third more sales. Milk determines the margin more than management does, and in the second quarter of 2026 exactly 0.1 million dollars of profit was left from 66.9 million dollars of net sales. Free cash flow was clearly negative in the first half of 2026, the revolving facility is 88 percent drawn, and cash has fallen to 7.1 million. Eighty-five percent of the range rests on one product, a quarter of net sales on two customers. And the ownership conflict is contained rather than settled: the chief executive's brother and mother together hold more shares than she does, roughly a quarter of the votes at the 2026 annual meeting went against the board, and the strategic suitor has closed the door behind him. Ten point seven million dollars of legal and advisory fees in two years show what that fight costs — money that did not go into plants and brands.

A human conclusion

We started with the streak trap: twenty-seven consecutive quarters sounds like proof. After reading the filings we know what it proves and what it does not. It proves that people increasingly like drinking this product — that is real, that is earned, and it is the harder half of a consumer business to build. It does not prove that any of it turns into profit. Between the bottle on the shelf and the profit sit the milk price, two retail chains that share the decision on price, a plant that is finishing later and dearer than announced, and an ownership fight that, together with the rebuffed takeover attempt, has cost 10.7 million dollars in legal and professional fees over two years.

The picture that remains: a company that is very good at selling and, so far, not good at keeping. 2027 is the year that decides it — the new plant runs, the margin is meant to return, and the company's own target of 45 to 50 million dollars of adjusted earnings has to be delivered. Until then every quarterly number is an interim report on exactly one question: is the margin coming back, or was the old margin the exception? Watching Lifeway does not require a price forecast. It requires three lines from the next quarterly report — the gross margin, the remaining headroom on the credit facility, and the sentence carrying the Waukesha cost estimate. They always sit in the same place. What you make of them is your decision.

Sources

• Form 10-Q for the quarter ended June 30, 2026 (filed 2026-08-13) — balance sheet, income statement, cash flow statement, customer concentration, debt obligations, Waukesha investment
• Form 8-K dated August 13, 2026, Exhibit 99.1 — second-quarter 2026 earnings release
• Form 10-K for 2025 (filed 2026-03-17) — product categories, routes to market, employees, risk factors, cooperation agreement with Danone, legal and professional fees
• Form 10-K for 2024 (filed 2025-03-14) — Danone's proposals at 25.00 and 27.00 dollars per share, rights agreement, credit agreement
• Form 10-K for 2023 (filed 2024-03-20) — 2023 comparatives
• Prospectus supplement 424B7 dated May 14, 2026 — full sale of the Danone stake, pricing, company repurchase
• Proxy statement DEF 14A dated April 30, 2026 — ownership as of 2026-04-30, chief executive compensation, effects of the cooperation agreement
• Form 8-K dated June 18, 2026, Item 5.07 — voting results of the June 17, 2026 annual meeting
• Form 8-K dated June 5, 2026 — redemption of the shareholder rights plan
• Form 8-K dated July 7, 2026 — equipment financing of up to 22.0 million dollars
• Transcripts of the earnings presentations of November 12, 2025 (third quarter 2025), March 17, 2026 (fourth quarter and full year 2025) and May 14, 2026 (first quarter 2026)
• Fundamental data: price, share count, free float, 52-week range, trailing four-quarter metrics — as of August 28, 2026

This text is journalistic analysis and not investment advice, not a buy or sell recommendation and not a solicitation to acquire or dispose of securities. All figures come from the sources named and carry their respective reporting dates. Shares can lose substantial value.